Skip to main content

Table 1 Characteristics of the 30 patients with Gram-negative VAP*

From: Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia

Parameter

Value

Age (year), median (IQR)

49 (33-57)

Sex, n (%)

 

   Male

23 (77)

   Female

7 (23)

Body height at inclusion, cm, median (IQR)

177 (167.9-182.9)

Body weight at inclusion, kg, median (IQR)

84 (78-91)

Primary reason for MV, n (%)

 

   Trauma

13 (44)

   Cardiac failure

4 (13)

   Postoperative respiratory failure

4 (13)

   Acute respiratory distress syndrome

3 (10)

   Coma/CNS disease

3 (10)

   Sepsis

2 (7)

   Pulmonary embolism

1 (3)

Tracheotomy, n (%)

7 (23)

Septic shock at inclusion, n (%)

2 (7)

Vasopressor use at inclusion, n (%)

5 (17)

MV duration before VAP onset, days, median (IQR)

9 (5-11)

Acute respiratory distress syndrome at inclusion, n (%)

5 (17)

PaO2/FIO2 ratio upon inclusion, mmHg, median (IQR)

210 (171-281)

  1. *Two of these patients were not included in the pharmacokinetic analysis because they did not received at least three full days of study medication.
  2. CNS = central nervous system; FiO2 = fraction of inspired oxygen; IQR = interquartile range; MV = mechanical ventilation; PaO2 = partial pressure of arterial oxygen; VAP = ventilator-associated pneumonia;